RA Capital Management
RA Capital Management, L.P. is a Boston-based venture capital firm that specializes in early and multi-stage investments in the healthcare and life sciences sectors. Founded in 2001, the firm focuses on companies developing drugs, medical devices, diagnostics, and biotechnology. RA Capital invests in a range of funding stages, from seed funding to later rounds, and is known for its willingness to invest under $1 million in initial rounds or larger sums in established companies. The firm's investment strategy emphasizes companies with promising technologies and products, particularly in areas like prevention, cost-effective diagnostics, genetic testing, and personalized medicine. The team consists of professionals with backgrounds in biology, chemistry, and medicine, enabling them to provide valuable insights into data, regulatory processes, and market demands. Additionally, RA Capital often seeks to co-invest and take board positions in its portfolio companies, enhancing their strategic growth opportunities.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.